Nicole C. Reyna
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nicole C. Reyna has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Ariyana LaCour
Department of Psychology, University of New Mexico, Albuquerque, NM, USA
1 shared publication- Benjamin J. Clark
Psychology Clinical Neuroscience Center, Department of Psychology, University of New Mexico, Albuquerque, NM 87131, USA
1 shared publication - Carlos Maestas-Olguin
Department of Psychology, University of New Mexico, Albuquerque, NM, USA
1 shared publication - Daniel D. Savage
Department of Neurosciences, School of Medicine, University of New Mexico, Albuquerque, NM 87106, USA
1 shared publication - Derek A. Hamilton
Department of Psychology, University of New Mexico, Albuquerque, NM, USA
1 shared publication - Enhui Wang
Department of Psychology, University of New Mexico, Albuquerque, NM, USA
1 shared publication
Latest Publications
- 20 May 2026
- Published by Wiley in Hippocampus
- Vol. 36 (3) , e70103
Effects of Corticotropin‐Releasing Factor 1 Receptor Antagonism on In Vivo Dentate Gyrus Long‐Term Potentiation in the TgF344 ‐ AD Rat Model of Alzheimer's Disease
Alzheimer's disease (AD) is characterized by irreversible neurobiological deterioration and cognitive impairment. AD patients exhibit stress system abnormalities including upregulation of the corticotropin releasing factor type 1 receptor (CRF 1 ) and elevated cortisol. Psychological distress increases the likelihood of AD diagnosis and hastens neurocognitive decline. Administration of the CRF 1 antagonist, Antalarmin, reduces AD pathogenesis and anxiety‐like behavior in models of AD. Motivated by these observations, the current study examined the potential contributions of CRF 1 to altered synaptic plasticity in AD neuropathology and stress in the TgF344‐AD rat model. In vivo electrophysiological recordings to assess long‐term potentiation (LTP) in the perforant pathway to dentate gyrus synapses were performed in aged transgenic rats and wild‐type (WT) controls (2–2.5 years). TgF344‐AD rats had abnormal LTP measures of field excitatory post‐synaptic potentials (fEPSP) and population spikes (PS). Treatment with Antalarmin did not alter LTP measures in TgF344‐AD or WT rats. These observations indicate that LTP in TgF344‐AD rats is reduced compared to WT rats and that acute treatment with a CRF 1 antagonist did not rescue LTP deficits. Future research should further examine the mechanism of CRF 1 in AD and implications of agonism or direct infusions of Antalarmin in vivo.
- 20 May 2026
- Published by Wiley in Hippocampus
- Vol. 36 (3) , e70103
Effects of Corticotropin‐Releasing Factor 1 Receptor Antagonism on In Vivo Dentate Gyrus Long‐Term Potentiation in the TgF344 ‐ AD Rat Model of Alzheimer's Disease
Alzheimer's disease (AD) is characterized by irreversible neurobiological deterioration and cognitive impairment. AD patients exhibit stress system abnormalities including upregulation of the corticotropin releasing factor type 1 receptor (CRF 1 ) and elevated cortisol. Psychological distress increases the likelihood of AD diagnosis and hastens neurocognitive decline. Administration of the CRF 1 antagonist, Antalarmin, reduces AD pathogenesis and anxiety‐like behavior in models of AD. Motivated by these observations, the current study examined the potential contributions of CRF 1 to altered synaptic plasticity in AD neuropathology and stress in the TgF344‐AD rat model. In vivo electrophysiological recordings to assess long‐term potentiation (LTP) in the perforant pathway to dentate gyrus synapses were performed in aged transgenic rats and wild‐type (WT) controls (2–2.5 years). TgF344‐AD rats had abnormal LTP measures of field excitatory post‐synaptic potentials (fEPSP) and population spikes (PS). Treatment with Antalarmin did not alter LTP measures in TgF344‐AD or WT rats. These observations indicate that LTP in TgF344‐AD rats is reduced compared to WT rats and that acute treatment with a CRF 1 antagonist did not rescue LTP deficits. Future research should further examine the mechanism of CRF 1 in AD and implications of agonism or direct infusions of Antalarmin in vivo.